The International Studies of Infarct Survival (ISIS) were four randomized controlled trials of several drugs for treating suspected acute myocardial infarction ("heart attack"). More than 134,000 patients from over 20 countries took part in four large simple trials between 1981 and 1993, coordinated from Oxford, England.[1][2]
ISIS-1 edit
The First International Study of Infarct Survival (ISIS-1) was a placebo-controlled trial of the beta-blocker atenolol. It recruited 16,027 patients and was completed in 1985.[3]
ISIS-2 edit
The Second International Study of Infarct Survival (ISIS-2) was a 2×2 factorial placebo-controlled trial of aspirin and the thrombolytic drug streptokinase. It recruited 17,187 patients and was completed in 1988.[4]
ISIS-3 edit
The Third International Study of Infarct Survival (ISIS-3) was a 3×2 factorial trial that compared the three thrombolytic drugs streptokinase, tissue plasminogen activator (tPA) and anistreplase to each other, and also compared the anticoagulant heparin to no heparin. All patients were also given aspirin. It recruited 41,299 patients and was completed in 1991.[5]
ISIS-4 edit
The Fourth International Study of Infarct Survival (ISIS-4) was a 2×2×2 factorial placebo-controlled trial of the angiotensin-converting enzyme inhibitor (ACE inhibitor) captopril, isosorbide mononitrate and magnesium sulphate. It recruited 58,050 patients and was completed in 1993.[6]
See also edit
- GISSI, an Italian group who conducted four similar large clinical trials
- Thrombolysis In Myocardial Infarction (TIMI)
- Myocardial infarction management
References edit
- ^ Hennekens, Charles H. (1998), "Trials of Thrombolytic Therapy: the International Studies of Infarct Survival Experience", Journal of Interventional Cardiology, 11: 1–7, doi:10.1111/j.1540-8183.1998.tb00089.x
- ^ Hennekens, Charles H.; Skerrett, P.J. (2005). "International Studies of Infarct Survival (ISIS)". Encyclopedia of Biostatistics. doi:10.1002/0470011815.b2a01031. ISBN 047084907X.
- ^ ISIS-1 (Second International Study of lnfarct Survival) Collaborative Group (1986), "Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1", The Lancet, 328 (8498): 57–66, doi:10.1016/S0140-6736(86)91607-7, S2CID 708900
{{citation}}: CS1 maint: numeric names: authors list (link) - ^ ISIS-2 (Second International Study of lnfarct Survival) Collaborative Group (1988), "Randomised Trial of Intravenous Streptokinase, Oral Aspirin, Both, or Neither Among 17 187 Cases of Suspected Acute Myocardial Infarction: ISIS-2", The Lancet, 332 (8607): 349–360, doi:10.1016/S0140-6736(88)92833-4, PMID 2899772, S2CID 21071664
{{citation}}: CS1 maint: numeric names: authors list (link) - ^ ISIS-3 (Third International Study of lnfarct Survival) Collaborative Group (1992), "ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction", The Lancet, 339 (8796): 753–770, doi:10.1016/0140-6736(92)91893-D, S2CID 560345
{{citation}}: CS1 maint: numeric names: authors list (link) - ^ ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group (1995), "ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction", The Lancet, 345 (8951): 669–682, doi:10.1016/S0140-6736(95)90865-X, S2CID 33961715
{{citation}}: CS1 maint: numeric names: authors list (link)